Compare · LPTX vs NVO
LPTX vs NVO
Side-by-side comparison of Leap Therapeutics Inc. (LPTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LPTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 1241.7x LPTX ($151.0M).
- Over the past year, LPTX is up 399.3% and NVO is down 41.7% - LPTX leads by 441.0 points.
- NVO has hit the wire 11 times in the past 4 weeks while LPTX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 5 for LPTX).
- Company
- Leap Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $1.60+269.43%
- $42.01-2.10%
- Market cap
- $151.0M
- $187.53B
- 1M return
- +232.79%
- -5.38%
- 1Y return
- +399.27%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 5
- 25
Leap Therapeutics Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LPTX
- SEC Form 4 filed by CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E
- SEC Form 4 filed by Director Li William
- SEC Form 4 filed by Director Richard Christian M
- SEC Form 4 filed by Director Mashiach Nissim
- SEC Form 4 filed by Director Martin Patricia A.
- SEC Form 4 filed by Director Schilsky Richard
- SEC Form 4 filed by Director Loscalzo Joseph
- SEC Form 4 filed by Director Cavanaugh James H
- SEC Form 4 filed by Director Mirabelli Christopher
- SEC Form 4 filed by Director Dietz Thomas John
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates